Novartis pulls ahead of Merck in METpositive lung cancer race
Novartis pulls ahead of Merck in MET-positive lung cancer race
06:23 EST 11 Feb 2020 |
PMLIVE
FDA starts priority review of Swiss pharma's MET inhibitor
Original Article: Novartis pulls ahead of Merck in MET-positive lung cancer race
More From BioPortfolio on "Novartis pulls ahead of Merck in MET-positive lung cancer race"